Novasign builds the digital infrastructure for modern bioprocess development. Founded in 2019 as a spin-off from BOKU University in Vienna, the company combines hybrid modeling, machine learning, and digital twin technology to accelerate biopharmaceutical and biotech innovation. The Novasign Studio platform enables scientists and engineers to reduce experimental workload by up to 70% while achieving robust process optimization through intelligent data-driven workflows.
The company serves clients across biopharmaceutical manufacturing, enzyme production, and precision fermentation sectors. Novasign's open ecosystem approach integrates seamlessly with third-party solutions, providing collaborative environments where data, models, and knowledge become actionable insights. With a strategic partnership with Repligen and a growing international team, Novasign is redefining how the biotech industry approaches process development and manufacturing optimization.
